Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Public ClinicalTrials.gov record NCT01161563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer
Study identification
- NCT ID
- NCT01161563
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Interventions
- Triptorelin pamoate Drug
- Leuprolide acetate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2010
- Primary completion
- Mar 31, 2011
- Completion
- Mar 31, 2011
- Last update posted
- Sep 5, 2013
2010 – 2011
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Watson Investigational Site | Homewood | Alabama | — | — |
| Watson Investigational Site | Daytona Beach | Florida | — | — |
| Watson Investigational Site | Orange City | Florida | — | — |
| Watson Investigational Site | Coeur d'Alene | Idaho | — | — |
| Watson Investigational Site | Carmel | Indiana | — | — |
| Watson Investigational Site | Jeffersonville | Indiana | — | — |
| Watson Investigational Site | Shreveport | Louisiana | — | — |
| Watson Investigational Site | Las Vegas | Nevada | — | — |
| Watson Investigational Site | Mount Laurel | New Jersey | — | — |
| Watson Investigational Site | Voorhees Township | New Jersey | — | — |
| Watson Investigational Site | Albany | New York | — | — |
| Watson Investigational Site | Syracuse | New York | — | — |
| Watson Investigational Site | Lancaster | Pennsylvania | — | — |
| Watson Investigational Site | Myrtle Beach | South Carolina | — | — |
| Watson Investigational Site | Dallas | Texas | — | — |
| Watson Investigational Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01161563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 5, 2013 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01161563 live on ClinicalTrials.gov.